Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib induction study in moderate to severe Crohn's disease
NL-OMON55413Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Upadacitinib with Placebo (2 arms). Primary endpoints: Clinical remission per patient-reported outcomes at Week 12 and Endoscopic response at Week 12. Started May 2019; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON55413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55413.